The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…
HOME > COMMENTARY
COMMENTARY
-
JPMA Update (10)
November 8, 2004
-
JPMA Update (9)
November 1, 2004
-
JPMA Update (8)
October 25, 2004
-
JPMA Update (7)
October 18, 2004
-
JPMA Update (6)
October 11, 2004
-
＜Special Contribution＞
October 4, 2004
-
JPMA Update (5)
October 4, 2004
-
JPMA Update(4)
September 27, 2004
-
JPMA Update (3)
September 20, 2004
-
JPMA Update (2)
September 13, 2004
-
＜New Series＞
September 6, 2004
-
June 7, 2004
-
BULLETIN
May 24, 2004
-
May 24, 2004
-
Brand Equity in the Pharmaceutical Industry
March 8, 2004
-
＜Special Contribution＞ Breakthrough Candidates from Japanese Pharmaceutical Industry in 2004 (2)
March 8, 2004
-
March 1, 2004
-
Pursuing the Value of the Japanese Pharm Industry (2)
February 9, 2004
-
＜New Series＞ Pursuing the Value of the Japanese Pharm Industry (1)
January 19, 2004
-
＜Special Contribution＞ Happy New Year to Japanese Pharmaceutical Stocks!
January 12, 2004
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…